C12N 2760/18534
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18534 (Use of virus or viral component as vaccine) appears on 478 US grants and 750 published applications in this corpus.
Search patents in C12N- Granted patents
- 478
- Published applications
- 750
- Assignees
- 300
- Inventors
- 1,162
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 5 | 0 |
| 1999 | 6 | 0 |
| 2000 | 7 | 0 |
| 2001 | 3 | 0 |
| 2002 | 6 | 8 |
| 2003 | 5 | 7 |
| 2004 | 5 | 14 |
| 2005 | 4 | 13 |
| 2006 | 2 | 7 |
| 2007 | 5 | 10 |
| 2008 | 3 | 8 |
| 2009 | 9 | 15 |
| 2010 | 9 | 22 |
| 2011 | 2 | 15 |
| 2012 | 0 | 23 |
| 2013 | 8 | 25 |
| 2014 | 15 | 34 |
| 2015 | 22 | 33 |
| 2016 | 22 | 39 |
| 2017 | 27 | 30 |
| 2018 | 23 | 33 |
| 2019 | 33 | 45 |
| 2020 | 29 | 49 |
| 2021 | 33 | 48 |
| 2022 | 40 | 67 |
| 2023 | 50 | 67 |
| 2024 | 38 | 64 |
| 2025 | 39 | 41 |
| 2026 | 18 | 33 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cell culture process for producing RSV F protein15 Sep 2026US 12,734,231 B2Pfizer Inc.
- Conformationally stabilized RSV pre-fusion F proteins11 Aug 2026US 12,703,721 B2
- Respiratory syncytial virus (RSV) polyanhydride nanoparticle vaccine14 Jul 2026US 12,678,410 B2University of Iowa Research Foundation
- Use of BCG immunogenic formulation expressing a respiratory syncitial virus protein against hMPV30 Jun 2026US 12,667,611 B2Pontificia Universidad Catolica De Chile
- Compositions, devices and methods for inducing immune responses to infectious agents16 Jun 2026US 12,653,888 B2Sigilon Therapeutics, Inc.
- Immunogenic compositions against influenza and rsv17 Sep 2026US 2026/0273040 A1Pfizer Inc.
- Rsv vaccine composition, method and use thereof10 Sep 2026US 2026/0263581 A1Sichuan Clover Biopharmaceuticals, Inc.
- Modified virus-like particles of cmv10 Sep 2026US 2026/0263612 A1Saiba GmbH
- Antigenic Multimeric Respiratory Syncytial Virus Polypeptides10 Sep 2026US 2026/0265309 A1Sanofi
- Methods of Isolating Poxviruses from Avian Cell Cultures27 Aug 2026US 2026/0248906 A1Bavarian Nordic A/S
Most cited
By later US patents
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Small liposomes for delivery of immunogen encoding RNA79US 9,254,265 B2Novartis AG · 2016
- Vaccination in newborns and infants79US 9,623,095 B2CureVac AG · 2017
- Modified live BRSV vaccine77US 5,733,555 AAmerican Home Products Corporation · 1998
- Vaccines for human respiratory virus74US 5,149,650 AThe University of North Carolina at Chapel Hill · 1992